Delivery Order SPE2DB20D3103-SPE2DB25FP2X0

Award Date 6/25/25
Potential Completion Date 7/17/25
Potential Value $26K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,672.15, is for the supply of ANDEXXA 200 MG VIALS, a pharmaceutical product. The contract is a firm fixed-price delivery order with a completion date of May 23, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $17,344.30 firm fixed-price contract is for the delivery of ANDEXXA 200 MG VIALS, a pharmaceutical product, with a completion date of July 17, 2025. This contract is not set aside and was awarded on an open competitive basis. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a wholly-owned subsidiary of Amerisourcebergen Corporation. The contract, valued at $7,570.17, is for the supply of ANDEXXA 200 MG VIALS, a specialty pharmaceutical product. This delivery order is issued under an indefinite delivery contract (IDC) with a total potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the supply of ANDEXXA 200 MG VIALS, a pharmaceutical product, with a ceiling value of $19,734.84 and a period of performance through March 15, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,931.53, is a delivery order for 4,568,075,871 vials of the medication ANDEXXA 200 MG. The contract is a firm fixed-price agreement with a period of performance ending on May 20, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of ANDEXXA 200MG VIALS 4S, a medical product, with a firm fixed price of $20,794.59 and a period of performance through May 29, 2025. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp is the prime contractor and holds a significant Indefinite Delivery Contract (IDC) with...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of ANDEXXA 200 MG VIALS, a pharmaceutical product, to the Defense Logistics Agency (DLA). The firm-fixed-price Delivery Order has a ceiling value of $13,317.46 and an ultimate completion date of August 5, 2024. The contract is not designated as a set-aside. Amerisourcebergen, a major pharmaceutical distribution company, holds a single-award Indefinite Delivery Contract (IDC) with the DLA...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $27,726.12 firm-fixed-price contract is for the supply of 4,567,955,833 units of the medication ANDEXXA 200 MG VIALS. The award has an ultimate completion date of May 8, 2025 and was made on April 17, 2025. This delivery order is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with DLA Troop Support...
The U.S. government has awarded a delivery order contract worth $15,050.28 to Amerisourcebergen Drug Corp's Corporate Office Division to provide the pharmaceutical product ANDEXXA 200 MG VIALS. This contract has no set-aside designation and is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. Under this IDC, Amerisourcebergen supplies a comprehensive range of...
This federal contract award, valued at $14,801.16, is a delivery order issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation, a for-profit pharmaceutical distribution company. The contract is for the supply of ANDEXXA 200 MG VIALS, a pharmaceutical product. The award is part of a larger indefinite delivery contract (IDC) between AmerisourceBergen Drug Corporation and DLA, valued at up to $999,999,999.00 and running through December 31, 2025....
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB25FP2X0
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of ANDEXXA 200 MG VIALS. The contract has a ceiling value of $26,016.45 and an ultimate completion date of July 17, 2025. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical support vehicle through December 2026. This delivery order is not designated as a set-aside contract, indicating open competition. The contract supports federal medical procurement needs, particularly for military and veteran healthcare systems.

Generated 9/24/25, 11:01 AM